BIO-TECHNE Corp 4

Bio-Techne Corp executive William Geist received new restricted stock unit awards totaling 38,747 shares of common stock on August 17, 2026 as part of his equity compensation.

On August 17, 2026, Bio-Techne Corp executive William Geist, President of Protein Sciences, received two new grants of time- and performance-based restricted stock units (RSUs) covering 14,762 and 23,985 shares of common stock, respectively, which are reported as acquisitions of derivative securities with no purchase price and vest over multiple future dates subject to continued service and, for performance RSUs, achievement and certification of specified performance goals. The filing also lists Geist’s existing equity incentives, including multiple tranches of stock options with exercise prices ranging from $53.60 to $100.39 and expirations between 2029 and 2035, as well as previously granted performance and time-based RSUs and restricted stock units with structured vesting schedules through 2029. These awards significantly increase Geist’s potential equity exposure to Bio-Techne but do not reflect any open-market purchases or sales; they are part of his compensation package, with ultimate value dependent on future stock performance and vesting conditions. Based on the absence of a trading price in the filing and the compensatory nature of the awards, the transactions appear routine incentive grants rather than signaling trades.

Filing Facts

CIK

842023

Ticker

TECH

Form

4

Source Type

fda

Accession

0000914190-26-000130

Alert Tier

5